Brokerages predict that Obalon Therapeutics Inc (NASDAQ:OBLN) will announce ($0.31) earnings per share for the current quarter, according to Zacks. Two analysts have issued estimates for Obalon Therapeutics’ earnings, with estimates ranging from ($0.36) to ($0.28). Obalon Therapeutics reported earnings of ($0.60) per share during the same quarter last year, which would indicate a positive year over year growth rate of 48.3%. The company is expected to issue its next earnings results on Monday, March 4th.
According to Zacks, analysts expect that Obalon Therapeutics will report full year earnings of ($1.89) per share for the current fiscal year, with EPS estimates ranging from ($1.93) to ($1.87). For the next year, analysts expect that the firm will post earnings of ($1.39) per share, with EPS estimates ranging from ($1.64) to ($1.14). Zacks’ EPS calculations are an average based on a survey of analysts that cover Obalon Therapeutics.
A number of research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Obalon Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 9th. Northland Securities reiterated a “hold” rating and set a $2.00 price objective on shares of Obalon Therapeutics in a report on Thursday, January 3rd. Finally, Roth Capital reiterated a “buy” rating on shares of Obalon Therapeutics in a report on Tuesday, February 5th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $4.54.
Shares of NASDAQ OBLN traded up $0.04 during mid-day trading on Friday, reaching $2.07. 53,327 shares of the company’s stock traded hands, compared to its average volume of 88,339. The stock has a market capitalization of $44.67 million, a P/E ratio of -1.00 and a beta of -0.98. Obalon Therapeutics has a 1-year low of $1.46 and a 1-year high of $4.60. The company has a debt-to-equity ratio of 0.47, a current ratio of 4.85 and a quick ratio of 4.58.
About Obalon Therapeutics
Obalon Therapeutics, Inc, a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. It offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc was founded in 2008 and is headquartered in Carlsbad, California.
Recommended Story: The Structure of a Futures Contract
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Obalon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.